Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) was the recipient of some unusual options trading on Wednesday. Investors purchased 4,063 put options on the company. This represents an increase of approximately 2,362% compared to the average daily volume of 165 put options. Xenon Pharmaceuticals Stock Performance Shares of XENE opened at $42.03 on Friday. The […]
Eversept Partners LP grew its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 6.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 275,704 shares of the biopharmaceutical company’s stock after purchasing an additional 16,092 shares during […]
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) reached a new 52-week high during trading on Tuesday . The company traded as high as $43.69 and last traded at $43.37, with a volume of 224615 shares. The stock had previously closed at $42.35. Analyst Ratings Changes A number of equities research analysts recently issued reports on […]
Driehaus Capital Management LLC grew its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) by 3.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 4,681,797 shares of the biopharmaceutical company’s stock after acquiring an additional 177,777 shares during the period. Xenon Pharmaceuticals comprises about 2.8% of Driehaus Capital Management LLC’s holdings, […]
Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) CEO Ian Mortimer sold 31,655 shares of the stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $41.41, for a total transaction of $1,310,833.55. Following the completion of the transaction, the chief executive officer now owns 24,213 shares of the […]